XML 67 R49.htm IDEA: XBRL DOCUMENT v3.19.1
Omeclamox®-Pak, Ethyol®, RediTrex®, Totect® and Vibativ® - Vibativ Acquisition - Schedule of Contingent Consideration and Preliminary Allocation (Details) - USD ($)
 1 Months Ended 2 Months Ended 12 Months Ended
Nov. 30, 2018
Dec. 31, 2018
Dec. 31, 2018
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Business Acquisition [Line Items]            
Cash paid at closing       $ 20,000,000 $ 0 $ 0
Goodwill   $ 784,000 $ 784,000 784,000 $ 0  
VIBATIV            
Business Acquisition [Line Items]            
Cash paid at closing $ 20,000,000.0     20,000,000    
Cash payment during early 2019       5,000,000    
Fair value of contingent consideration - net sales royalty       9,034,000    
Total consideration       34,034,000    
Balance at November 12, 2018   9,034,000        
Change in fair value of contingent consideration included in operating expenses   (40,000)        
Contingent consideration earned and accrued in operating expenses     508,000      
Balance at December 31, 2018   $ 9,502,000 $ 9,502,000 $ 9,502,000    
Finished goods inventory 6,624,000          
Work in process - unlabeled vials 3,970,000          
Work in process - validation vials 1,827,000          
Raw materials 9,129,000          
Total inventory 21,550,000          
Intellectual property amortizable intangible assets 11,700,000          
Goodwill 784,000          
Total intangibles and goodwill 12,484,000          
Total assets acquired $ 34,034,000